GSK-5458514

N/A

Report date: 2026/04/25 20:00:23

Base Information

Drug NameGSK-5458514

Drug Alias NameGSK5458514GSK-5458514

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-PSMAT lymphocytes stimulantsImmunologic cytotoxicity

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesFrance +[5]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A